normal karyotype. Several studies have concluded that the morphologic defect of hydrops rather than the chromosome abnormality may be associated with the positive screen for Down syndrome and the subsequent identification of fetal Turner syndrome (5, 14 ) . More recently, Saller et al. (15 ) investigated maternal serum analyte concentrations in euploid pregnancies and concluded that nonimmune hydrops is associated with increased hCG. It has been reported that two fetuses with nuchal thickening and a subsequent probable diagnosis of Noonan syndrome were associated with a positive Down syndrome screen related to decreased AFP and increased hCG (16 ) . It is not known whether those pregnancies with an identifiable cystic hygroma would have subsequently developed hydrops. Laundon et al. (7 ) included all fluid collection in the category of hydrops, including hygroma and cysts, and found increased free ␤hCG associated with Turner syndrome. Our data combined with that of Saller et al. (5 ) , Knowles and Flett (4 ) , and Laundon et al. (7 ) reveal that 30 of 34 fetuses with fluid collection (hydrops, hygroma, and cysts) were screen positive. In our sample of 19 fetuses, 4 (21%) had an increased Down syndrome risk and 1 (5%) had an increased trisomy 18 risk without abnormalities on ultrasound. Overall, 74% (14 of 19) of our cases had a positive screen: 2 with a neural tube risk, 11 with a Down syndrome risk, and 1 with a trisomy 18 risk. Recently, inhibin A concentrations were moderately decreased in cases of Turner syndrome without hydrops but markedly increased in cases of Turner syndrome with hydrops (17 ) .
As has been reported previously, the maternal serum AFP and uE 3 concentrations were slightly reduced in pregnancies affected with Turner syndrome. In addition, hCG concentrations were increased in fetal Turner syndrome but more so in hydropic pregnancies. Based on these findings, some cases of Turner syndrome may be identified prenatally as a result of an increased risk for Down syndrome when these markers are used. Thus, women with an increased risk of Down syndrome based on multiple-marker screening should be counseled that Turner syndrome may be a possibility, even in the absence of fetal hydrops. The ascertainment of two fetuses with Turner syndrome as the result of increased trisomy 18 risk suggests that Turner syndrome may be given as a possible explanation for an increased trisomy 18 risk. We wished to investigate the mechanism of decreased serum vitamin K 1 after bone fractures. Vitamin K 1 plays a role in bone formation because it is required as a cofactor for the transformation of glutamic acid (Glu) residues on proteins to ␥-carboxyglutamic acid (Gla) residues. The double carboxy group on Gla residues has high affinity for the binding of calcium. Bone formation involves vitamin K-dependent small peptide osteocalcin (boneGla-protein) that is secreted by osteoblasts.
What Happens to
Serum concentrations of vitamin K 1 reflect in part the capacity of the serum to carry the vitamin. Vitamin K 1 is a lipid, and little is known about the binding of this vitamin to proteins other than that it is transported in serum by the lipoproteins. It is not known whether there is a specific "vitamin K 1 -binding protein" in tissues as has been suggested for vitamin E as a "tocopherol-binding protein" (1 ) .
Deficiency of vitamin K will lead to defective ␥-carboxylation of vitamin K-dependent proteins and will be Clinical Chemistry 45, No. 12, 1999 manifested by the failure of these proteins to function normally (2) (3) (4) (5) (6) (7) (8) . Low serum concentrations of vitamin K 1 have been reported to occur in patients with traumatic bone fractures (4 -6 ), although others have reported nonsignificant decreases in vitamin K 1 in the immediate 48 h after low-energy trauma hip fracture (9 ) . These serum concentrations were considered pathological because they were significantly lower than values in age-matched control subjects. Recent studies, however, have shown that even very low absolute concentrations of vitamin K 1 in serum do not reflect the vitamin K status (3, 10, 11 ) . The use of a relative measure of serum vitamin K 1 , the ratio of vitamin K 1 to lipids (11 ) or to apolipoproteins (3, 12 ) , has become essential in evaluating vitamin K 1 nutritional status as has been shown for vitamin E (11 ). Under routine conditions, the ratios of vitamin K 1 and vitamin E to other plasma lipoproteins components are relatively constant. Changes in the metabolism of lipoproteins such as are the case with hypercholesterolemia do not seem to affect such ratios (3, 11 ) .
Stepwise linear regression methods have determined that serum concentrations of vitamin K 1 could best be predicted by using equations excluding lipids but containing only apolipoprotein A 1 and B concentrations:
. The correlation coefficient between the calculated values of vitamin K 1 using serum concentrations of apolipoproteins A 1 and B and the measured (HPLC) values of vitamin K 1 was 0.83 (3 ) .
It has been suggested that the low serum concentrations of vitamin K 1 observed in patients with traumatic bone fractures was a consequence of sequestration of this vitamin from the circulation for use at the fracture site where it is required for the Gla transformation of special bone peptides (4 ) .
LDL, which contains apolipoprotein B, is a negative acute phase reactant and is induced by inflammation (13, 14 ) such as with traumatic bone fractures. A decrease in synthesis and an increase in degradation of apolipoprotein B have been shown to occur. The reduction in apolipoprotein B concentration is reflected by a reduction in serum LDL concentrations as has been shown after acute myocardial infarction (13, 14 ) . Consequently, because of the relationship of vitamin K 1 and apolipoprotein B (3 ), this may reflect the reduction in serum vitamin K 1 concentrations observed in patients soon after fracture. Thus it is possible that the lower concentration of vitamin K 1 in serum observed after bone fracture is attributable to a generalized lipoprotein carrier phenomenon (the negative acute phase response of LDL), which is an alternative explanation to the sequestration of vitamin K 1 from its carrier to bone fracture site.
To test whether the metabolism of vitamin K 1 in patients with bone fractures is altered independently of the lipoprotein carrier system, we measured vitamin K 1 (15 ) and apolipoproteins A 1 and B (3, 16 ) in sera from eight patients admitted for treatment of traumatic bone fractures in the pelvis. The sera were collected from all male patients (mean age, 45.0 years; range, 15-64 years) within 10 days (range, 1-9 days) of sustaining the fracture (4 ). The exclusion criteria were blood transfusions or surgical procedures before the period of sample collection and past and present illnesses related to bone metabolism. No subjects had been treated for osteoporosis, and none received medications before or during the study that might have affected calcium metabolism.
Serum samples were also taken from 12 healthy male subjects (mean age, 46.4 years; range, 19 -55 years) for analyses of vitamin K 1 , apolipoprotein A 1 , and apolipoprotein B. There was no statistical difference (Student t-test) between the ages of controls and patients with fractures. Informed consent was obtained from all participants. The procedures used for these human studies were in accord with the Helsinki Declaration of 1975, as revised in 1996.
Serum vitamin K 1 concentrations from all subjects were also calculated by applying derived equations containing apolipoproteins A 1 
and B concentrations (3 ).
The mean serum concentration of vitamin K 1 was significantly lower in the fracture patients than in the control subjects, but the concentrations of apolipoproteins A 1 and B were not significantly different in the two groups (Table 1) .
When vitamin K 1 concentrations in serum were calculated by the equation:
, the obtained mean value for the control subjects was 348 g/L, similar to the value of 361 g/L ( Table 1 ). The ratio of corresponding individual measured/calculated values of vitamin K 1 in serum was 1.04 (SD ϭ 0.04).
In contrast, the calculated mean concentration of vitamin K 1 from the bone fracture patients, 369 g/L, was a The results are expressed as mean Ϯ SD; the concentration ranges are shown in parentheses. Vitamin K 1 concentrations were assayed by an established liquid chromatographic procedure (15) . Apolipoproteins A 1 and B were measured by immunoassays (16) . Vitamin K 1 was calculated by the formula: significantly different (P Ͻ0.01) from the measured mean concentration of 221 g/L ( Table 1 ). The ratio of corresponding individual measured/calculated values of vitamin K 1 in serum of bone fracture patients was 0.60 (SD ϭ 0.13). This ratio was significantly different (P Ͻ0.001) from that of the control subjects ( Table 1) .
The current results confirm that the circulating serum vitamin K 1 concentrations are reduced shortly (within 10 days) after bone fracture (4 -7 ) . It is known that vitamin K 1 deficiency occurs in elderly subjects (6 ) . However, in our study, because all the subjects were males and their ages were not relatively old, together with the fact that the age range of the controls was similar to that of the patients, it is unlikely that age had an effect on our observations. In control subjects, vitamin K 1 concentrations in serum can be calculated from the concentrations of apolipoproteins A 1 and B (3 ) . However, in patients after bone fracture, the changes in serum vitamin K 1 concentrations are not paralleled with changes in their carrier systems, the lipoproteins. There is no evidence that after bone fracture apolipoprotein A 1 and B concentrations in serum are altered. It appears that serum vitamin K 1 is utilized independent of its lipoprotein carriers in serum. These observations support the concept that this vitamin is sequestered from lipoproteins in the circulation for use, perhaps at the fracture site (4 ). The current results indicate that the mode of sequestration of vitamin K 1 is independent of the metabolism of lipoproteins, an observation that has not previously been reported. In patients without bone fractures, the vitamin K 1 concentration can be predicted from the concentrations of apolipoproteins A 1 and B, whereas it cannot be predicted by the same equation in patients with bone fractures. The mechanism of vitamin K 1 delivery to the fracture site remains to be elucidated, but it could conceivably operate via a putative receptor in which the vitamin K 1 is selectively taken up, analogous to the interaction of HDL with cells without the loss of its apolipoprotein components. This study further indicates a need to validate the use of equations containing the serum concentrations of apolipoproteins A 1 Prostate-specific antigen (PSA) is a member of the human kallikrein family of serine proteases that for a long time was thought to be produced exclusively by the epithelial cells of the prostate gland (1 ). Because of its tissue specificity, PSA has been widely used as a marker for diagnosing and monitoring prostate cancer (2 ) . However, recent studies have demonstrated the widespread distribution of PSA in a variety of tumor types, healthy tissues, and biological fluids [reviewed in Ref. (3 ) ]. Although the physiological role and the biological significance of extraprostatic PSA currently are unknown, it has been suggested that this serine protease should be regarded as a growth factor regulator produced by cells bearing steroid hormone receptors (4, 5 ) . Several studies have biochemiClinical Chemistry 45, No. 12, 1999 
